

ASX Announcement 10 November 2020

## Therapeutic Goods Administration (TGA) Approval for CONVIVO<sup>®</sup> and Sterile Sheath in Australia

Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') has been informed by Carl Zeiss Meditec AG (CZM) that the CONVIVO<sup>®</sup> and the Sterile Sheath (which acts as a sterile barrier between the probe of the CONVIVO<sup>®</sup> and the tissue in the brain) have both been registered on the Australian Register of Therapeutic Goods enabling those devices to be lawfully supplied for use in neurosurgery in Australia. These registrations are in addition to approvals previously received by CZM to market the CONVIVO<sup>®</sup> in the United States and Europe as CZM continues the full commercialization of the CONVIVO<sup>®</sup>, developed as part of the co-operation agreement between CZM and Optiscan.

- ends -

This announcement has been authorised for release by the Board of Optiscan.

## For investor queries, please contact:

Darren Lurie CEO and Executive Chairman – Optiscan Imaging Limited E: <u>dlurie@Optiscan.com</u>

## **About Optiscan**

Optiscan is a global leader in the development of microscopic imaging and related technologies for screening, surgery and medical research. Based in Melbourne, Australia, Optiscan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level – instant "virtual biopsies" with applications for cancer screening and surgical margin determination. Optiscan's technology has the capability to improve patient welfare, reduce hospital costs, improve accuracy and reduce the need for multiple procedures. The technology is approved for use in brain surgery and is involved in a number of oral cancer and breast cancer studies.

## Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.